Launching a UK weight management clinic with GLP-1 receptor agonists in 2026 requires three things: clinical compliance with NICE NG23 and NG87 where applicable, GDP-compliant cold-chain dispensing, and a patient pathway that includes proper screening, monitoring, and follow-up. The category is high-volume, high-LTV, and under tight regulatory watch. This piece is the launch brief for founders entering it.
Category regulatory landscape — NICE, MHRA, GPhC overlap
GLP-1 receptor agonists for weight management in the UK have a defined regulatory landscape. NICE guidance NG23 (Obesity) and NG87 (Weight management) frame clinical use. MHRA oversees medicines licensing and post-market surveillance. GPhC oversees the dispensing pharmacy. CQC oversees the clinical service. Weight management has been a specific MHRA enforcement focus across 2024-2026 — operators entering this category should expect scrutiny, not assume it.
BMI thresholds, screening, and clinical eligibility
Standard BMI thresholds for GLP-1 prescribing in the UK align with NICE-aligned criteria. Patients below threshold without comorbidities are not appropriate candidates. Clinical screening should cover medical history, current medications, mental-health history, pregnancy status, and family history of medullary thyroid carcinoma or MEN-2. Without proper screening, off-label prescribing risk compounds — and off-label without documented clinical justification is a known MHRA enforcement target.
Cold-chain dispensing — GLP-1 requires GDP-compliant handling
GLP-1 receptor agonists are cold-chain medicines requiring 2-8°C storage and transport. Dispensing them under UK Good Distribution Practice (GDP) means validated packaging, monitored temperature through the chain, qualified shippers, and exception handling when shipments break temperature. Launching a GLP-1 brand without cold-chain capability is not viable. PExpo's brand model includes GDP-compliant cold-chain dispensing as standard — see our brand model page.
Patient pathway — initiation, titration, monitoring, follow-up
GLP-1 patient pathways follow a defined arc: initiation at low dose, titration with monitoring, ongoing follow-up at defined intervals, and structured decision points for continuation or discontinuation. Patients should be reviewed clinically at each titration step. Annual or six-monthly metabolic monitoring is appropriate for many patients. A patient pathway that just refills automatically without review is not defensible at inspection.
Adverse event management and Yellow Card reporting
GLP-1 receptor agonists have a defined adverse event profile. The patient pathway must include capture of suspected adverse events, clinical assessment by the responsible prescriber, and Yellow Card submission where criteria are met. Under-reporting in this category is a known MHRA focus area. Pharmacovigilance is the function that protects the operator as much as the patient — treat it as both.
Marketing and advertising — the line you cannot cross
Prescription-only medicines cannot be advertised to the public in the UK. Weight management brands cannot name GLP-1 medicines, suggest brand specificity, or make comparative efficacy claims in public-facing marketing. ASA and MHRA have enforced on multiple brands across 2024-2026. Marketing the service is legitimate; marketing the medicine is not. The line is narrow and enforced when crossed.
Prescription-only medicines cannot be advertised to the public in the UK. ASA and MHRA have enforced on multiple weight management brands across 2024-2026 — marketing the service is legitimate; marketing the medicine is not.
Launching a GLP-1 brand without cold-chain capability is not viable. The dispensing operation is foundational, not optional.
Launching a UK weight management clinic with GLP-1 is a regulated build with high commercial upside and high enforcement attention. The operators who treat NICE alignment, cold-chain dispensing, patient pathway discipline, and advertising compliance as foundational launch sustainably. The ones who shortcut any of them launch fast and remediate slowly. See our brand model page for the white-label option that includes cold-chain dispensing and clinical governance, or our clinic model page if you operate a clinic and want to add weight management.
Frequently asked questions
What do I need to launch a UK weight management clinic with GLP-1?
Clinical compliance with NICE NG23 and NG87 where applicable, MHRA-aligned medicines handling, a GPhC-registered dispensing pharmacy (or partner), GDP-compliant cold-chain capability, and a patient pathway with proper screening, monitoring, and follow-up. PExpo's brand model includes the clinical workflow, prescriber network, and cold-chain dispensing as a managed stack.
What is GDP-compliant cold-chain dispensing?
Good Distribution Practice (GDP) is the UK framework for storing and transporting medicines — for cold-chain products like GLP-1 receptor agonists, that means 2-8°C with documented temperature monitoring across storage, packing, courier handover, and last-mile delivery. Validated packaging and qualified shippers are required.
Can I advertise GLP-1 medicines by name in the UK?
No. Prescription-only medicines cannot be advertised to the public under the Human Medicines Regulations 2012. Weight management brands can market the clinical service but cannot name medicines, suggest brand specificity, or make comparative efficacy claims. ASA and MHRA enforce this strictly.
How does PExpo support GLP-1 telehealth brands?
PExpo's brand model includes the clinical workflow, UK prescriber network, clinical governance framework, and GDP-compliant cold-chain dispensing as a single integrated stack. The brand operates patient-facing and PExpo operates the regulated layers behind it. See our brand model page for the full scope.
